Larazotide FAQ: common questions answered
An oral gut-barrier peptide with mixed celiac results and a stopped phase 3 trial.
Also called: Larazotide acetate, AT-1001, AT1001, INN-202, NM-001.
Gut peptides · Oral tight-junction regulator; proposed zonulin-pathway antagonist.
- Is Larazotide FDA-approved? No FDA label or approved indication located. Trial or emergency-use authorization is not marketing approval.
- How do people take it? By mouth, three times daily. One month reported. Source: reported by users, not an established dose.
- What's the difference between Larazotide and KPV? Larazotide: an oral gut-barrier peptide with mixed celiac results and a stopped phase 3 trial. KPV: an alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial. Why people pair them: people combine it with larazotide hoping to address inflammation and gut-barrier symptoms.
- Can I take it with KPV? People combine it with larazotide hoping to address inflammation and gut-barrier symptoms. No human combination trial found; benefit and added risk are unknown. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Inference from the S0 rule for unapproved investigational drugs; larazotide is not named individually. Confirm with the relevant anti-doping body.
- How do I store it once opened? No validated home-mixed stability or beyond-use period was found.
Related to Larazotide
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- KPV: An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding, FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- Risks of buying peptide products online, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Understanding the Risks of Compounded Drugs, FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Darmerica, LLC - 716152 - 12/08/2025, FDA · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease., Rubio-Tapia A et al. · The American journal of gastroenterology · 2023
- Anaphylaxis, NHS · NHS · 2023
- Stomach ache, NHS · 2023
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.